Incyte Q1 revenue $1.27B (+21% YoY), Non-GAAP EPS $1.81 beats prior $1.16; pipeline expands

INCYTE CORP

2026-Q1 EPS reported $1.47 revenue$1,272,676,000

Total net sales $1.10B (+20% YoY); Jakafi $758M (+7%), Opzelura $143M (+20%), Hem/Onc $204M (+116%).
GAAP net income $303M ($1.47 diluted EPS) vs $158M ($0.80) prior year; Non-GAAP diluted EPS $1.81.
Positive Phase 3 vitiligo results for povorcitinib; NDA accepted for HS; four product approvals/launches expected in next 12 months.
Appointed Suketu Upadhyay as CFO effective May 4, 2026; cash position $4.0B.
FY 2026 guidance reaffirmed: total net sales $4.77-$4.94B; R&D and SG&A expenses guided.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

INCYTE CORP reported first quarter of 2026 results: revenue $1.27 billion.

Period: first quarter of 2026
Revenue: $1.27 billion
Result: reported results

Exact text from the filing

furnished as Exhibit 99.1. --- EX-99.1 (EX-99.1) --- FOR IMMEDIATE RELEASE Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates Total revenue of $1.27 billion and total net sales of $1.10 billion in the first quarter of 2026, an increase of 21% and 20% respectively, compared to the first quarter of 2025 Jakafi ® (ruxolitinib) net sales

View on SEC.gov

1447 earnings releases filed in the last 30 days. Browse all earnings releases →

INCYTE CORP filing history →

Source: SEC EDGAR

accession 0000879169-26-000023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.